NICE recommends golimumab as a possible treatment for people with psoriatic arthritis in the same circumstances as other drugs for this condition (see 'Who can have golimumab?1' below).
Who can have golimumab?1
You should be able to have golimumab if you have three tender and three swollen joints and you have already tried at least two disease-modifying drugs (DMARDs), given on their own or together, but they haven't worked.
Only people whose psoriatic arthritis improves enough by 12 weeks should be able to carry on with treatment.
When assessing whether your psoriatic arthritis has improved, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.
1The circumstances described in this section are the same circumstances in which NICE recommends etanercept, infliximab and adalimumab.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.